NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021)
NeuroPace (NPCE) recorded quarterly Total Non-Current Liabilities of $60.1 million in Q4 2021, up 1.29% quarter-over-quarter from $59.3 million in Q3 2021, and down 3.26% on a YoY basis from $62.1 million in Q4 2020.
NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
NeuroPace's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $60.1 million for Q4 2021.
- In Q4 2021, Total Non-Current Liabilities fell 3.26% year-over-year to $60.1 million; the TTM figure through Dec 2021 stood at $60.1 million (down 3.26% YoY), while the FY2021 annual figure was $60.1 million, down 3.26% from the prior year.
- Total Non-Current Liabilities was $60.1 million for Q4 2021 at NeuroPace, up from $59.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $65.1 million in Q1 2021 to a low of $58.3 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 40.52 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 15.78 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 2.44 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 9.85 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 3.53 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 3.47 Bn |
| 10 | NeuroPace | 527.50 Mn | 473.52 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 60.06 Mn |
| Sep 30, 2021 | 59.30 Mn |
| Jun 30, 2021 | 58.30 Mn |
| Mar 31, 2021 | 65.06 Mn |
| Dec 31, 2020 | 62.09 Mn |